Gly1057Asp polymorphism of insulin receptor substrate-2 is associated with coronary artery disease in the Taiwanese population
© Chan et al.; licensee BioMed Central Ltd. 2012
Received: 10 October 2012
Accepted: 30 November 2012
Published: 5 December 2012
Gly1057Asp polymorphism in insulin receptor substrate (IRS)-2 is related to insulin resistance and diabetes mellitus (DM), which both contribute to the pathogenesis of coronary artery disease (CAD). Hence, we hypothesize that Gly1057Asp polymorphism in IRS-2 is associated with CAD.
Patients receiving elective coronary angiography were enrolled. Significant stenosis is defined as a luminal diameter stenosis greater than 50%. Patients without significant stenosis were defined as group A, and those with significant stenosis in at least one major coronary artery were defined as group B. Genotypes were determined by polymerase chain reaction/restriction fragment length polymorphism. Chi-square test and multivariate logistic regression were used to evaluate the relationship between Gly1057Asp polymorphism in IRS-2 and CAD. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as a representative of insulin resistance. Multiple linear regression was used to analyze the association between Gly1057Asp polymorphism in IRS-2 and the HOMA-IR index.
There were 170 patients in group A and 284 patients in group B. The Gly allele frequencies were 54.7% for group A and 60.9% for group B (p = 0.077). The Gly/Gly + Gly/Asp genotype frequency was 74.1% for group A and 84.9% for group B (p = 0.007). After adjustments for conventional risk factors in multivariate logistic regression, the odds ratio for CAD in patients with the Gly/Gly + Gly/Asp genotype was 2.008 [95% confidence interval (95% CI) = 1.210-3.332, p = 0.007], using patients with the Asp/Asp genotype as a reference group. The concurrence of Gly1057Asp polymorphism in IRS-2 with DM is correlated with occurrence of CAD. In multivariate logistic regression, employing non-diabetics with the Asp/Asp genotype as a reference group, the odds ratio for CAD was 1.561 [95% CI = 0.517-4.713, p = 0.430] for diabetics with the Asp/Asp genotype, 1.922 [95% CI = 1.086-3.400, p = 0.025] for non-diabetics with the Gly/Gly + Gly/Asp genotype, and 3.629 [95% CI = 1.820-7.236, p < 0.001] for diabetics with the Gly/Gly + Gly/Asp genotype. There was no association between Gly1057Asp polymorphism in IRS-2 and HOMA-IR index.
Gly allele at codon 1057 in IRS-2 is correlated with an increased susceptibility to CAD in the Taiwanese population. There is a synergistic effect toward CAD between the pathogenicity of DM and that of the Gly allele.
KeywordsInsulin receptor substrate Diabetes mellitus Coronary artery disease Single nucleotide polymorphism Insulin resistance Homeostasis model assessment
There is evidence that coronary artery disease (CAD) is associated with genetic factors . Both insulin resistance [2–4] and diabetes mellitus (DM)  are risk factors for CAD. Thus, the genetic variants involved in the development of insulin resistance and DM may be associated with the susceptibility to CAD.
Insulin binding to its receptors leads to activation of several intracellular downstream effectors. Among these, insulin receptor substrate (IRS) proteins are most important . Insulin activates the insulin receptor substrate/phosphatidylinositol 3-kinase (IRS/PI3-K) pathway and the Ras/mitogen-activated protein kinase (MAPK) pathway. The IRS/PI3-K pathway mediates insulin-dependent glucose transport, whereas the Ras/MAPK pathway promotes insulin-mediated cell growth and proliferation. Resistance in the glucose regulation pathway is referred to as insulin resistance. Hyperinsulinemia occurs during insulin resistance due to stimulation of pancreatic β-cell activity. Other pathways are probably over-stimulated due to hyperinsulinemia. The chronic effects of the hyperinsulinemia cause dyslipidemia, higher blood pressure, or platelet hypercoagulation that contribute to CAD pathogenesis .
Genetic polymorphism in the IRS plays a role in insulin resistance related disorders . Gly972Arg polymorphism caused by a single nucleotide polymorphism (SNP) in IRS-1 is associated with impaired IRS-1 function , reduced insulin sensitivity , as well as an increased susceptibility to type 2 DM  and CAD . IRS-2 is an alternative effector protein in the insulin signaling pathway . IRS-2 gene knockout mice exhibit a phenotype similar to human type 2 DM . In humans, Gly1057Asp polymorphism in IRS-2 is caused by a SNP in the IRS-2 gene (rs1805097) . Middle-aged glucose-tolerant Danish males who carry the Asp allele have shown decreased serum insulin and C-peptide concentrations during oral glucose tolerance tests . A study of an Italian population reported that the Asp allele increases the risk for type 2 DM in obese subjects, while lean subjects have a decreased risk. Among non-diabetic individuals, fasting C-peptide levels are inversely related to the dosage of the Asp allele . A study of the Chinese Han population also concluded that lean subjects with the Asp allele have a decreased risk for DM, while obese subjects have an increased risk . These data suggest that the Asp allele is associated with a lower risk of insulin resistance and DM in lean individuals. On the contrary, the Gly1057Asp polymorphism in IRS-2 is not associated with insulin resistance in Finnish subjects . The CC genotype of the -756C/T SNP in the promoter region of IRS-2 is associated with an increased susceptibility to CAD , which suggests that genetic variants of IRS-2 may be associated with occurrence of CAD. Until now, there are no reports of a relationship between Gly1057Asp polymorphism in IRS-2 and CAD.
The frequency of the Gly allele at codon 1057 in IRS-2 is common in the Chinese Han population . Since most Taiwanese are descendants of Mainland Chinese, they have similar genetic backgrounds. The prevalence of Gly1057Asp polymorphism in IRS-2 is probably common in the Taiwanese. Because CAD shares common risk factors with DM, it is possible that the genetic backgrounds for CAD and DM are similar. Because the Asp allele at codon 1057 in IRS-2 seems to be associated with the low risk of insulin resistance and DM [15, 16], we hypothesize that the Asp allele plays a protective role for CAD. In this study, we investigated the relationship between Gly1057Asp polymorphism in IRS-2 and CAD in the Taiwanese population.
A hospital-based cross-sectional study was conducted. Patients older than 18 years old receiving coronary angiography for stable angina pectoris, suspected CAD, or pre-operation examination for structural heart disease were enrolled. We aimed at investigating the association between the Gly1057Asp polymorphism in IRS-2 and coronary atherosclerosis rather than coronary thrombosis; thus, patients with acute myocardial infarction were excluded. Besides, we intended to perform follow-up angiography if indicated; patients with serum creatinine levels greater than 221 μmol/L were excluded to avoid contrast-induced nephropathy. Patient histories of conventional CAD risk factors were obtained. The definitions of hypertension (HTN), type 2 DM, and hypercholesterolemia were in accordance with the relevant reports [20–22]. In brief, a patient was considered to have HTN if a seated blood pressure greater than 140/90 mmHg had been documented on at least two or more office visits, or if antihypertensive medications had been used. Type 2 DM was defined as being present if the patient was under treatment for DM at the time of admission to the study, or if their fasting blood glucose levels had been greater than 7 mmol/L on two or more separate occasions. Hypercholesterolemia was defined as being present if the patient was being treated at the time of enrollment or if their fasting blood total cholesterol levels had been greater than 5.18 mmol/L. Body mass index (BMI) was calculated using the formula: body weight in kilograms divided by the square of body height in meters (kg/m2). The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated in 190 patients of the entire cohort. The HOMA-IR index is a validated tool for estimating insulin resistance, and is calculated as follows: fasting insulin (μIU/ml) × fasting glucose (mmol/ml)/22.5 [23, 24]. Blood samples were drawn after at least 8 hours overnight fasting. Fasting plasma sugar was checked by using the standard hexokinase method. Radioimmunoassay was used to check the fasting serum insulin levels. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki  and was approved by the ethics committee of National Cheng Kung University Hospital. After a thorough explanation of the study and its contents, each patient gave their informed consent.
Detection of Gly1057Asp polymorphism in IRS-2 by polymerase chain reaction (PCR) and restriction fragment length polymorphism (see Additional file 1 and 2)
Definition of CAD was as described previously . Luminal stenosis was defined as significant when the luminal diameter of the major coronary artery, or one of its major branches, showed a reduction of 50% or greater. Major coronary arteries included left main artery, left anterior descending coronary artery, left circumflex coronary artery, and right coronary artery. The major branches of right coronary artery included posterior descending artery and posterolateral branch, the major branch of left circumflex coronary artery was the major obtuse marginal branch, and the major branch of left anterior descending coronary artery was the major diagonal branch. The decision of coronary arteries with significant luminal stenosis was determined by two independent investigators by visual determination.
The main object of current study is to evaluate the relationship between Gly1057Asp polymorphism in IRS-2 and CAD. Patients without significant luminal stenosis were defined as group A and those with significant stenosis in at least one proper major coronary artery or its major branches were defined as group B. Since the frequency of Gly allele at codon 1057 in IRS-2 in diabetic patients is about 65% for the Chinese Han population , and assuming this Gly allele frequency for patients in group B and a 10% difference for patients with the Gly allele in group A, we estimated that 200 patients were needed for each group to provide a two-tailed α of 0.05 and a power of 80%.
For continuous variables, results were presented as mean with standard deviation (SD), and the differences between groups were checked by the independent Student T test. Categorical variables were presented using frequency counts, and intergroup comparisons were analyzed by the chi-square test. A multivariate binary logistic regression analysis was used for CAD prediction. All variables were included in multivariate logistic analysis (enter method). The effect of a risk factor was expressed as an odds ratio (OR) and a 95% confidence interval (95% CI). A multiple linear regression analysis was used to investigate the correlation of variables, including conventional CAD risk factors and genotype, with the HOMA-IR index. Unstandardized regression coefficients (B coefficients) were calculated to show the relationship between the variables and the HOMA-IR index. Standardized regression coefficients (beta coefficients) were also calculated to reveal the effect of each variable on the HOMA-IR index; this allowed the magnitudes of the regression coefficients to be compared and indicated which variable played an important role . The detailed methods were described in Additional file 3 (see Additional file 3).
The concern about multicollinearity in multivariate logistic or multiple linear regression analysis was checked by calculating the variance inflation factor (VIF). Variables with a VIF value greater than 2.5 were considered to have significant multicollinearity with other independent variables. Consequently, any independent variable with a VIF value greater than 2.5 was considered to be dropped from the analysis to avoid multicollinearity, after taking into account the practical aspect and importance of each variable. A p-value of less than 0.05 (two-tailed) was considered significant. All analyses were done using SPSS for WINDOWS, version 12.0 (Chicago, IL, United States).
Group A (n = 170)
Group B (n = 284)
59.0 ± 13.5
63.6 ± 10.7
Body mass index (kg/m2)
25.5 ± 4.0
25.7 ± 3.4
Serum creatinine (μmol/L)
84.8 ± 23.7
94.2 ± 26.0
Total cholesterol (mmol/L)
4.8 ± 0.9
5.0 ± 1.0
Frequency of Gly1057Asp polymorphism in IRS-2 in patient cohort
Allele and genotype frequency of Gly1057Asp polymorphism of insulin receptor substrate-2
Allele frequency [number of alleles (%)]
Group A (n = 340)
Group B (n = 568)
Genotype frequency [ number of individuals (%)]
Group A (n = 170)
Group B (n = 284)
Gly/Gly + Gly/Asp
Asp + Asp
Relationship between Gly1057Asp polymorphism in IRS-2 and CAD
Logistic regression analysis of the relationship between Gly1057Asp polymorphism in IRS-2 and CAD*
Odds ratio (95% CI) (Univariate analysis)
Odds ratio (95% CI) (Multivariate analysis)
Asp/Asp(n = 87)
Gly/Gly + Gly/Asp(n = 367)
Body mass index(kg/m2)
Relationship between the concurrence of Gly1057Asp polymorphism in IRS-2 with DM and CAD
Logistic regression analysis of the relationship between genotype-DM interaction and CAD*
Odds ratio (95% CI) (Univariate analysis)
Odds ratio (95% CI) (Multivariate analysis)
Nondiabetics:Asp/Asp(n = 68)
Diabetics:Asp/Asp(n = 18)
Nondiabetics:Gly/Asp + Gly/Gly(n = 261)
Diabetics:Gly/Asp + Gly/Gly(n = 107)
Body mass index(kg/m2)
Relationship between Gly1057Asp polymorphism in IRS-2 and insulin resistance
Linear regression analysis for prediction of HOMA-IR index
Unstandardized coefficient (B)
Unstandardized coefficient (B)
Standardized coefficient (beta)
Gly1057Asp polymorphism in IRS-2
Asp/Asp(n = 41)
Gly/Gly(n = 69) + Gly/Asp(n = 80)
Body mass index(kg/m2)
Our study demonstrated an association between Gly1057Asp polymorphism in IRS-2 and CAD. Additionally, we produced evidence that the Gly1057Asp polymorphism in IRS-2 interacts with DM in relation to risk of CAD; there is a synergistic effect toward CAD between pathogenicity of DM and that of the Gly allele.
In our study population, the Gly/Gly and Gly/Asp genotype frequencies for CAD patients were significantly greater than in control subjects (Table 2). These results suggest that the Gly allele positively correlates with the occurrence of CAD, and therefore the Asp allele has a protective effect against CAD. In multivariate binary logistic regression, the odds ratio of CAD was 2.008 for patients with Gly/Gly and Gly/Asp genotypes and 1.847 for those with DM. These results suggest that the Gly1057Asp polymorphism in IRS-2 is independent of DM as a risk factor for CAD and that both Gly allele at codon 1057 in IRS-2 and DM are potent risk factors for CAD (Table 3). Importantly, we found that the concurrence of Gly allele with DM is associated with an increased susceptibility to CAD (Table 4). In patients with either Asp/Asp genotypes or Gly/Gly and Gly/Asp genotypes, the odds ratio for CAD in diabetics is almost twice that of their non-diabetic counterparts, which is compatible with the results reported in the Framingham study . In non-diabetics, the odds ratio for CAD in those with Gly/Gly and Gly/Asp genotypes was 1.922, which was about twice the ratio for those with Asp/Asp genotypes. Similarly, in diabetics, the odds ratio for CAD in those with Gly/Gly and Gly/Asp genotypes was 3.629, which was roughly twice the ratio for patients with Asp/Asp genotypes. Further, the odds ratio for CAD in diabetics with Gly/Gly and Gly/Asp genotypes was 3.629, which was roughly four times the ratio found in non-diabetics with Asp/Asp genotypes (Table 4). These results suggest that the pathogenic ability of the Gly allele to cause CAD is similar to that of DM. They also suggest a synergistic effect between the pathogenicity of DM and that of the Gly allele. We found that there was no correlation between Gly1057Asp polymorphism in IRS-2 and insulin resistance irrespective of BMI values (Table 5) and obesity (Additional file 4). These results probably exclude the possibility that the Gly1057Asp polymorphism in IRS-2 contributes to CAD through altering insulin resistance.
Several studies have already reported that genetic variants caused by a SNP are associated with CAD, including adiponectin receptor 2 gene [29, 30], apolipoprotein E gene , and genes related to regulation of blood lipid levels . In current study, we found the concurrence of Gly1057Asp polymorphism in IRS-2 with DM affects the susceptibility to CAD. This interaction between Gly1057Asp polymorphism in IRS-2 and DM could be a kind of gene-environmental or gene-gene interaction. DM itself or genes contributory to development of DM could interact Gly1057Asp polymorphism in IRS-2 to influence the susceptibility to CAD. Similar findings for interrelation of genetic variants and DM in relation to disease traits have been reported. Genetic variants of transcriptional factor 7-like 2 gene are associated with CAD, which are significantly modulated by the presence of type 2 DM . Besides, the +183 A/G polymorphism at the 3’-untranslated region of interleukin (IL)-18 genes is associated with the circulating IL-18 levels, especially apparent in patients with type 2 DM and metabolic syndrome . The frequency of Gly allele was 58.6% in our study subjects, which was approximately equal to that found in Chinese and Finnish patients . We found that Gly1057Asp polymorphism in IRS-2 was not associated with insulin resistance, which was consistent with studies of Finnish subjects . However, the Asp allele was reported to be correlated with better insulin sensitivity in specific groups in Danish  and Italian  populations. This discrepancy may be due to differences in ethnics, or to heterogeneous demographic characteristics. Thus, further investigation is needed to clarify the relationship between Gly1057Asp polymorphism in IRS-2 and insulin resistance.
DM is a potent risk factor for CAD . However, the susceptibility to CAD is different among diabetic patients. In diabetic patients concomitantly with other conventional risk factors for CAD such as hypercholesterolemia and hypertension, the risk for cardiovascular events in the following 5 to 10 years actually increases much more than that for their counterparts [35–37]. Therefore, genetic screening for Gly1057Asp polymorphism in IRS-2 may be a plausible method to early detect diabetic patients with high susceptibilities to CAD.
Our study is a cross-sectional study. The inherent weakness of cross-sectional studies is an inability to indicate causality because the predictor variable is not shown to precede the outcome. However, the predictor variable that we were interested in for this study, Gly1057Asp polymorphism in IRS-2, was determined by the time the study subjects were born. Hence, the results of our study do demonstrate a causal relationship between Gly1057Asp polymorphism in IRS-2 and CAD. Nonetheless, there were several limitations to this study. First, the number of patients for our main objective, investigating the relationship between Gly1057Asp polymorphism in IRS-2 and CAD, was limited. The number of control patients was 170, which is less than the calculated sample size of 200 patients required to achieve a power of 80% with a two-tailed α of 0.05. Thus, a larger scale study is needed to strengthen the present results. The study was also limited in that it was a hospital-based study. There may have been selection bias. Our study subjects were not truly representative of the overall population. Therefore, a general population-based study is needed to confirm our findings. Using multi-slice computed tomography to screen coronary arteries may be a feasible method for this purpose. When we investigated the relationship between Gly1057Asp polymorphism in IRS-2 and insulin resistance we studied only 190 of the total 454 patients. Also, we checked the insulin resistance by calculating the HOMA-IR index rather than by using the gold standard method euglycemic hyperinsulinemic clamp. Hence, our conclusion that there is no correlation between Gly1057Asp polymorphism in IRS-2 and insulin resistance should be further confirmed by an investigation using euglycemic hyperinsulinemic clamp on a larger scale. Finally, although we showed a correlation between Gly1057Asp polymorphism in IRS-2 and CAD, we did not afford the molecular mechanisms underlying this correlation.
We demonstrated that Gly allele at codon 1057 in IRS-2 is correlated with an increased susceptibility to CAD and that there is a synergistic effect between this polymorphism and DM that increases a person’s susceptibility to CAD. Individual genetic screening for this common polymorphism may facilitate the management of patients, especially for diabetic patients. Further well-designed studies are needed to support our results and to investigate possible clinical and therapeutic applications.
Body mass index
Coronary artery disease
Homeostasis model assessment of insulin resistance
Insulin receptor substrate
Insulin receptor substrate/phosphatidylinositol 3-kinase
Mitogen-dependent protein kinase
Polymerase chain reaction
Single nucleotide polymorphism
Variance inflation factor.
We are grateful to Sheng-Hsiang Lin and Jia-Ling Wu for providing the statistical consulting service from the Biostatistics Consulting Center, National Cheng Kung University Hospital, Tainan, Taiwan.
- Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994, 330: 1041-1046. 10.1056/NEJM199404143301503.View ArticlePubMed
- Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS: Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham heart study. Arterioscler Thromb Vasc Biol. 2011, 31: 1208-1214. 10.1161/ATVBAHA.110.219055.PubMed CentralView ArticlePubMed
- Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-1607. 10.2337/diabetes.37.12.1595.View ArticlePubMed
- DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991, 14: 173-194. 10.2337/diacare.14.3.173.View ArticlePubMed
- Kannel W, McGee D: Diabetes and cardiovascular risk factors: the framingham study. Circulation. 1979, 59: 8-13. 10.1161/01.CIR.59.1.8.View ArticlePubMed
- White MF: The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998, 182: 3-11. 10.1023/A:1006806722619.View ArticlePubMed
- Korenman SG, Kahn CR: Atlas of Clinical Endocrinology, Volume 2, Diabetes. 1999, United Kindom: Wiley-Blackwell
- Kahn CR: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994, 43: 1066-1084.View ArticlePubMed
- Almind K, Inoue G, Pedersen O, Kahn CR: A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest. 1996, 97: 2569-2575. 10.1172/JCI118705.PubMed CentralView ArticlePubMed
- Clausen JO, Hansen T, Bjorbaek C, Echwald SM, Urhammer SA, Rasmussen S, Andersen CB, Hansen L, Almind K, Pedersen O, Borch-Johnsen K, Winther K, Haraldsdòttir J: Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet. 1995, 346: 397-402. 10.1016/S0140-6736(95)92779-4.View ArticlePubMed
- Burguete-Garcia AI, Cruz-Lopez M, Madrid-Marina V, Lopez-Ridaura R, Hernández-Avila M, Cortina B, Gómez RE, Velasco-Mondragón E: Association of Gly972Arg polymorphism of IRS1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a candidate gene study. Metab Clin Exp. 2010, 59: 38-45. 10.1016/j.metabol.2009.07.007.View ArticlePubMed
- Baroni MG, D’Andrea MP, Montali A, Pannitteri G, Barilla F, Campagna F, Mazzei E, Lovari S, Seccareccia F, Campa PP, Ricci G, Pozzilli P, Urbinati G, Arca M: A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 1999, 19: 2975-2980. 10.1161/01.ATV.19.12.2975.View ArticlePubMed
- Araki E, Lipes MA, Patti M-E, Bruning JC, Haag Iii B, Johnson RS, Kahn CR: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 1994, 372: 186-190. 10.1038/372186a0.View ArticlePubMed
- Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren J-M, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998, 391: 900-904. 10.1038/36116.View ArticlePubMed
- Almind K, Frederiksen SK, Bernal D, Hansen T, Ambye L, Urhammer S, Ekstrøm CT, Berglund L, Reneland R, Lithell H, White MF, Van Obberghen E, Pedersen O: Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Diabetologia. 1999, 42: 1244-1249. 10.1007/s001250051299.View ArticlePubMed
- Mammarella SRF, Di Valerio A, Creati B, Esposito DL, Palmirotta RCF, Vitullo P, Volpe G, Battista P, Della LF, Mariani-Costantini R, Cama A: Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol Genet. 2000, 9: 2517-2521. 10.1093/hmg/9.17.2517.View ArticlePubMed
- Kong LF, Zhao YY, Li Q, Zheng XM, Ding Q, Liu H, GL L: Study on the relationship between G1057D variants of IRS2 gene and obese T2DM in Chinese Han subjects. Chin J Medical Genetics. 2005, 22: 387-390.
- Wang H, Rissanen J, Miettinen R, Kärkkäinen P, Kekäläinen P, Kuusisto J, Mykkänen L, Karhapää P, Laakso M: New amino acid substitutions in the IRS-2 gene in Finnish and Chinese subjects with late-onset type 2 diabetes. Diabetes. 2001, 50: 1949-1951. 10.2337/diabetes.50.8.1949.View ArticlePubMed
- Hagg DA, Jernas M, Wiklund O, Thelle DS, Fagerberg B, Eriksson P, Hamsten A, Olsson B, Carlsson B, Carlsson LM, Svensson PA: Expression profiling of macrophages from subjects with atherosclerosis to identify novel susceptibility genes. Int J Mol Med. 2008, 21: 697-704.PubMed
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003, 289: 2560-2572. 10.1001/jama.289.19.2560.View ArticlePubMed
- Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.View Article
- World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO consultation. 2006, Geneva: World Health Organization
- Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.View ArticlePubMed
- Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care. 2004, 27: 1487-1495. 10.2337/diacare.27.6.1487.View ArticlePubMed
- Shephard DA: The 1975 declaration of helsinki and consent. Can Med Assoc J. 1976, 115: 1191-1192.PubMed CentralPubMed
- Li YH, Chen JH, Wu HL, Shi GY, Huang HC, Chao TH, Tsai WC, Tsai LM, Guo HR, Wu WS, Chen ZC: G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am J Cardiol. 2000, 85: 8-12.View ArticlePubMed
- Dawson B, Trapp RG: Basic and clinical biostatistics. 2004, United States of America: Lange Medical Books/McGraw-Hill, 4
- WHO Regional Office for the Western Pacific: The asia-pacific perspective: redefining obesity and its treatment. 2000, Manila, Phillippines: World Health Organization
- Halvatsiotis I, Tsiotra PC, Ikonomidis I, Kollias A, Mitrou P, Maratou E, Boutati E, Lekakis J, Dimitriadis G, Economopoulos T, Kremastinos DT, Raptis SA: Genetic variation in the adiponectin receptor 2 (ADIPOR2) gene is associated with coronary artery disease and increased ADIPOR2 expression in peripheral monocytes. Cardiovasc Diabetol. 2010, 9: 10-10.1186/1475-2840-9-10.PubMed CentralView ArticlePubMed
- Siitonen N, Pulkkinen L, Lindstrom J, Kolehmainen M, Schwab U, Eriksson JG, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M: Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individuals with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Cardiovasc Diabetol. 2011, 10: 83-10.1186/1475-2840-10-83.PubMed CentralView ArticlePubMed
- Chaudhary R, Likidlilid A, Peerapatdit T, Tresukosol D, Srisuma S, Ratanamaneechat S, Sriratanasathavorn C: Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 2012, 11: 36-10.1186/1475-2840-11-36.PubMed CentralView ArticlePubMed
- Shah S, Casas JP, Gaunt TR, Cooper J, Drenos F, Zabaneh D, Swerdlow DI, Shah T, Sofat R, Palmen J, Kumari M, Kivimaki M, Ebrahim S, Smith GD, Lawlor DA, Talmud PJ, Whittaker J, Day IN, Hingorani AD, Humphries SE: Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. Eur Heart J. 2012, 13: 13-
- Muendlein A, Saely CH, Geller-Rhomberg S, Sonderegger G, Rein P, Winder T, Beer S, Vonbank A, Drexel H: Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. PLoS One. 2011, 6: e17978-10.1371/journal.pone.0017978.PubMed CentralView ArticlePubMed
- Opstad TB, Pettersen AA, Arnesen H, Seljeflot I: Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol. 2011, 10: 110-10.1186/1475-2840-10-110.PubMed CentralView ArticlePubMed
- Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation. 1998, 97: 1837-1847. 10.1161/01.CIR.97.18.1837.View ArticlePubMed
- Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular munster (PROCAM) study. Circulation. 2002, 105: 310-315. 10.1161/hc0302.102575.View ArticlePubMed
- New Zealand Guidelines Group: The assessement and management of cardiovascular risk. 2003, New Zealand: Wellington
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.